REXAHN PHARMACEUTICALS INC's ticker is RNN and the CUSIP is 761640101. A total of 1 filers reported holding REXAHN PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $21,000 | +250.0% | 40,400 | 0.0% | 0.00% | – |
| Q4 2016 | $6,000 | -33.3% | 40,400 | 0.0% | 0.00% | – |
| Q3 2016 | $9,000 | -10.0% | 40,400 | 0.0% | 0.00% | – |
| Q2 2016 | $10,000 | -28.6% | 40,400 | 0.0% | 0.00% | – |
| Q1 2016 | $14,000 | -6.7% | 40,400 | 0.0% | 0.00% | – |
| Q4 2015 | $15,000 | -28.6% | 40,400 | 0.0% | 0.00% | – |
| Q3 2015 | $21,000 | -12.5% | 40,400 | 0.0% | 0.00% | – |
| Q2 2015 | $24,000 | -20.0% | 40,400 | 0.0% | 0.00% | – |
| Q1 2015 | $30,000 | +30.4% | 40,400 | +25.5% | 0.00% | – |
| Q4 2014 | $23,000 | -20.7% | 32,200 | -10.6% | 0.00% | – |
| Q3 2014 | $29,000 | -9.4% | 36,000 | 0.0% | 0.00% | – |
| Q2 2014 | $32,000 | -17.9% | 36,000 | 0.0% | 0.00% | – |
| Q1 2014 | $39,000 | +34.5% | 36,000 | -50.0% | 0.00% | – |
| Q4 2013 | $29,000 | +81.2% | 72,000 | +100.0% | 0.00% | – |
| Q3 2013 | $16,000 | 0.0% | 36,000 | 0.0% | 0.00% | – |
| Q2 2013 | $16,000 | – | 36,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Northeast Financial Consultants Inc | 150,000 | $130,000 | 0.07% |
| Benin Management CORP | 83,000 | $72,000 | 0.04% |
| CONDOR CAPITAL MANAGEMENT | 114,987 | $100,000 | 0.03% |
| FIRST NEW YORK SECURITIES LLC /NY | 15,000 | $13,050,000 | 0.01% |
| Advisory Services Network, LLC | 22,000 | $19,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 180,000 | $157,000 | 0.00% |
| Moors & Cabot, Inc. | 25,000 | $22,000 | 0.00% |
| Corbenic Partners LLC | 1,600 | $1,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 4,566 | $4,000 | 0.00% |
| AQR Capital Management | 213,900 | $186,000 | 0.00% |